There are currently 535 clinical trials in Gainesville, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Florida /ID# 144834, University of Florida Health Science Center - Gainesville, University of Florida Shands Cancer Center and University of Florida College of Medicine. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis
NCT06080789
Recruiting
The goal of this clinical trial is to test the safety and effectiveness of a single dose of RABI-767 given by endoscopic ultrasound (EUS) guided peripancreatic injection in participants with predicted severe acute pancreatitis. The main question the study aims to answer is: • Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection safe in patients with predicted severe acute pancreatitis. The study also aims to answer: • Is a single-dose of RABI-767 given by EUS-guided peri... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
02/19/2025
Locations: University of Florida Health, Gainesville, Florida
Conditions: Acute Pancreatitis
Register for Updates
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
NCT06480383
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD who have an inadequate response to ongoing GAD treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Clinical Site, Gainesville, Florida
Conditions: Generalized Anxiety Disorder
Register for Updates
Naxitamab for High-Risk Neuroblastoma Patients with Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone And/or Bone Marrow
NCT03363373
Recruiting
Children and adults diagnosed with high-risk neuroblastoma patients with primary refractory disease or incomplete response to salvage treatment in bone and/or bone marrow will be treated for up to 101 weeks with naxitamab and granulocyte-macrophage colony stimulating factor (GM-CSF). Patients will be followed for up to five years after first dose. Naxitamab, also known as hu3F8 is a humanised monoclonal antibody targeting GD2
Gender:
ALL
Ages:
1 year and above
Trial Updated:
02/18/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Neuroblastoma
Register for Updates
MCG As a Noninvasive Diagnostic Strategy for Suspected INOCA (MICRO2)
NCT06212466
Recruiting
A prospective, multicenter, observational, single-arm trial to validate CardioFlux MCG's ability to diagnose myocardial ischemia caused by coronary microvascular dysfunction in patients with suspected ischemia and confirmed no obstructive coronary artery disease (suspected INOCA) by using diagnostic measures of coronary flow reserve (CFR) via invasive angiography as a reference standard for diagnosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/18/2025
Locations: University of Florida, Division of Cardiovascular Medicine, Gainesville, Florida
Conditions: Ischemic Heart Disease, Coronary Microvascular Disease, Angina, Myocardial Ischemia
Register for Updates
Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study
NCT06016946
Recruiting
This project is a global, multicenter, prospective, longitudinal, observational natural history study that can be used to understand the disease progression and support the development of safe and effective drugs and biological products for Friedreich ataxia.
Gender:
ALL
Ages:
All
Trial Updated:
02/17/2025
Locations: University of Florida - Neurology, Gainesville, Florida
Conditions: Friedreich Ataxia
Register for Updates
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04589845
Recruiting
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/14/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Solid Tumors
Register for Updates
REBYOTA™ Prospective Registry
NCT05835219
Recruiting
This is a prospective observational cohort study designed to collect data on patients who received REBYOTA™ for the prevention of rCDI in the routine care setting. As all data collected for this study are observational, the decision to prescribe REBYOTA™ is at the treating physician's discretion and independent from the decision to enroll the patient in the study. Data will be collected from patients' medical records after obtaining informed consent. Data about clinical history, CDI events (prim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Ferring Investigational Site, Gainesville, Florida
Conditions: Recurrence of Clostridium Difficile Infection
Register for Updates
NP-G2-044 As Monotherapy and Combination Therapy in Patients with Advanced or Metastatic Solid Tumor Malignancies
NCT05023486
Recruiting
Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of continuously dosed NP-G2-044 monotherapy and NP-G2-044 in combination with anti-PD-1 therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/11/2025
Locations: University of Florida (UF) - Shands Cancer Center, Gainesville, Florida
Conditions: Advanced or Metastatic Solid Tumor Malignancies
Register for Updates
Healthy Aging Through Movement
NCT05772884
Recruiting
This study aims to examine the effectiveness of a supervised aerobic exercise program for persons with Opioid Use Disorder (OUD). Participants will be enrolled in a 12-week supervised aerobic exercise intervention.
Gender:
ALL
Ages:
Between 21 years and 64 years
Trial Updated:
02/10/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Opioid Use Disorder
Register for Updates
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT05774951
Recruiting
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
02/10/2025
Locations: Research Site, Gainesville, Florida
Conditions: Breast Cancer, Early Breast Cancer
Register for Updates
High-protein Oral Supplement With Liposomal Curcumin in Adults Undergoing Hemodialysis.
NCT06381076
Recruiting
A 12-week double-blind randomized control trial will be conducted among adults on hemodialysis (n=15) to determine the impact of liposomal curcumin in a high-protein product on inflammation markers and oxidative stress. Participants will be randomized via a computer-generator into either the control or intervention group. Participants in each group will be given a total of 38 g of a high protein product with or without 7 mls of liposomal curcumin for a total of 8 weeks. At baseline, weeks 8 and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Chronic Kidney Disease 5D
Register for Updates
Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics
NCT06401577
Recruiting
The DREAM-ON study will investigate whether continuous glucose monitoring (CGM) is useful to predict risk for developing diabetes mellitus (DM) and pre-diabetes mellitus (PDM), the need for insulin therapy among those who develop DM, and to determine whether CGM can provide insight into the pathophysiology and DM subtype among participants who have experienced an episode of acute pancreatitis (AP). Thus, the results of the DREAM-ON study could inform future clinical practice guidelines for the m... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/07/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Acute Pancreatitis
Register for Updates